The estimated Net Worth of Michael Kagnoff is at least $2.99 millió dollars as of 4 March 2020. Mr. Kagnoff owns over 10,000 units of GenMark Diagnostics Inc stock worth over $2,841,913 and over the last 10 years he sold GNMK stock worth over $0. In addition, he makes $145,373 as Independent Director at GenMark Diagnostics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Kagnoff GNMK stock SEC Form 4 insiders trading
Michael has made over 10 trades of the GenMark Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of GNMK stock worth $46,100 on 4 March 2020.
The largest trade he's ever made was buying 20,000 units of GenMark Diagnostics Inc stock on 6 November 2017 worth over $82,600. On average, Michael trades about 3,211 units every 96 days since 2015. As of 4 March 2020 he still owns at least 118,216 units of GenMark Diagnostics Inc stock.
You can see the complete history of Mr. Kagnoff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Kagnoff biography
Michael S. Kagnoff serves as Independent Director of the Company. Mr. Kagnoff has served as a partner of the law firm of DLA Piper LLP (US), the Company’s outside corporate counsel, since April 2008. Prior to joining DLA Piper LLP (US), Mr. Kagnoff served as a partner of Heller Ehrman LLP. Mr. Kagnoff has advised boards of directors of public and private companies for over 20 years, with a focus on representing life sciences and technology companies on a wide range of topics, including strategic transactions and corporate governance and compensation matters. Mr. Kagnoff received a B.A. and B.S. degree from the University of Pennsylvania and a J.D. from the University of California, Berkeley’s Boalt Hall School of Law.
What is the salary of Michael Kagnoff?
As the Independent Director of GenMark Diagnostics Inc, the total compensation of Michael Kagnoff at GenMark Diagnostics Inc is $145,373. There are 8 executives at GenMark Diagnostics Inc getting paid more, with Scott Mendel having the highest compensation of $1,749,300.
How old is Michael Kagnoff?
Michael Kagnoff is 51, he's been the Independent Director of GenMark Diagnostics Inc since 2015. There are 6 older and 3 younger executives at GenMark Diagnostics Inc. The oldest executive at GenMark Diagnostics Inc is Daryl Faulkner, 71, who is the Independent Director.
Insiders trading at GenMark Diagnostics Inc
Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem és Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.
What does GenMark Diagnostics Inc's logo look like?
Complete history of Mr. Kagnoff stock trades at GenMark Diagnostics Inc
GenMark Diagnostics Inc executives and stock owners
GenMark Diagnostics Inc executives and other stock owners filed with the SEC include:
-
Scott Mendel,
President, Chief Executive Officer, Director -
Johnny Ek,
Chief Financial Officer -
Michael Gleeson,
Senior Vice President, Corporate Accounts -
Eric Stier,
Senior Vice President, General Counsel, Secretary -
James Fox,
Non-Executive Independent Director -
Kevin O'Boyle,
Independent Chairman of the Board -
Lisa Giles,
Independent Director -
Daryl Faulkner,
Independent Director -
Michael Kagnoff,
Independent Director -
Tyler Jensen,
Senior Vice President - Engineering and Product Technical Support -
Jon Faiz Kayyem,
President & CEO -
Jennifer Anne Williams,
SVP Global Operations -
Wade R. Stevenson,
SVP, North America Sales -
Brian Andrew Mitchell,
SVP, Operations -
Christine Shaw,
VP, Assay Development -
John Frederick Ek,
Chief Financial Officer -
Richard B Slansky,
Chief Financial Officer -
Stephen T Worland,
Director -
Jeffrey Alan Hawkins,
SVP, Marketing & Bus Dev -
Ingo Chakravarty,
SVP, International -
Christopher M Gleeson,
Director -
James B. Mc Nally,
SVP, Marketing and Bus. Dev. -
Jorge Garces,
SVP, Research & Development -
Paul Ross,
CFO & Secretary -
Pankaj Singhal,
Sr. VP, Product Dev & Mftg -
Matthew Robert Cohen,
SVP, Gen Counsel & Secretary -
John Bellano,
SR. VP, Commercial Operations -
Steven J Kemper,
CFO, Treasurer & Secretary -
Bradley Calvin,
Senior VP, Global Marketing -
Scott Alexander O'brien,
SVP, Global Mktg & Int'l Sales -
Hany Massarany,
President and CEO -
Sarah Hollis Winkler,
VP, Human Resources -
Alan Baer Maderazo,
VP, Qual, Reg, & Clin Affairs -
Michael John Harkins,
SVP, Sales -
Abdul Chohan,
SVP Operations